LitCovid-sentences  

PMC:7076992 / 2074-3826 JSONTXT 13 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T17 0-74 Sentence denotes Convalescent plasma: one of the forgotten immunologically based strategies
T18 75-152 Sentence denotes Passive immunization has been successfully used to treat infectious diseases.
T19 153-411 Sentence denotes A meta-analysis demonstrated a significant reduction in mortality and viral load in studies using convalescent plasma for the treatment of severe acute viral respiratory infections, including those caused by related coronaviruses (SARS-CoV and MERS-CoV) [5].
T20 412-453 Sentence denotes Serious adverse events were not reported.
T21 454-544 Sentence denotes Eighty SARS patients were treated with convalescent plasma during the last major outbreak.
T22 545-677 Sentence denotes A significantly better outcome was obtained with earlier transfusion (before day 14), and no immediate adverse events were observed.
T23 678-967 Sentence denotes A feasibility intervention study of convalescent plasma for MERS-CoV infection treatment failed to identify sufficient high-titer plasma from patients with confirmed/suspected MERS, their close family members, or healthcare workers exposed to MERS (n = 12 reactive ELISA/443 serum tested).
T24 968-1079 Sentence denotes Two fresh-frozen plasma units (250–350 mL/unit) would be required for each enrolled MERS patient (NCT02190799).
T25 1080-1186 Sentence denotes Encouragingly, anti-MERS CoV titers measured by ELISA correlated with microneutralization (MN) assays [6].
T26 1187-1335 Sentence denotes There are currently over 30,000 recovered COVID-19 patients, who could present a valuable resource of convalescent plasma for health care providers.
T27 1336-1526 Sentence denotes China National Biotec Group Co has claimed that 10 seriously ill patients receiving this immunoglobulin therapy demonstrated improved oxygenation and reduced inflammation and viral load [7].
T28 1527-1752 Sentence denotes High-titer specific antibodies should be able to bind to SARS-CoV-2 and neutralize the viral particles, block access to uninfected cells, and activate potent effector mechanisms (e.g., complement activation and phagocytosis).